---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-016715"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-01-26T23:59:59+00:00"
generated_at: "2026-06-06T16:28:51.578956+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology raises $150M via oversubscribed private placement at 29% premium

## Summary
- $150M gross proceeds from sale of 1.38M shares and 7.32M pre-funded warrants at $17.25/share.
- 29% premium to Jan 23 close; lead investors include EcoR1 Capital, Deerfield affiliate, Suvretta Capital.
- Pro forma cash, equivalents, and investments expected to fund operations into 2027.
- Net proceeds to support R&D for clinical-stage candidates and general corporate purposes.
- Virtual investor event on Jan 30 to highlight preliminary ziftomenib combination data from KOMET-007.

## SEC filing metadata
- accession: 0001193125-24-016715
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312524016715/0001193125-24-016715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312524016715/d642740d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-016715
- JSON: https://secwatch.observer/filing/0001193125-24-016715.json
- Plain text: https://secwatch.observer/filing/0001193125-24-016715.txt

## Key facts
- Material Agreements
  Kura Oncology, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors named therein valued at approximately $150.0 million (effective 2024-01-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors named therein
  - Value: approximately $150.0 million
  - Effective: 2024-01-24
  source text: On January 24, 2024, Kura Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) (i) an aggregate of 1,376,813 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $17.25 per share, and (ii), in lieu of shares of Common Stock to certain Purchasers, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 7,318,886 shares of Common Stock (the “Warrant Shares”) at a purchase price of $17.2499 per Pre-Funded Warrant (representing the $17.25 per Share purchase price less the exercise price of $0.0001 per Warrant Share).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312524016715/0001193125-24-016715-index.htm
- Material Agreements
  Kura Oncology, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-01-26).
  - Action: entry
  - Counterparty: the Purchasers
  - Effective: 2024-01-26
  source text: On January 26, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Warrant Shares held by the Purchasers (the “Registrable Securities”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312524016715/0001193125-24-016715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.